Introduction
Multiple sclerosis (MS), an inflammatory demyelinating disease of the central nervous system (CNS), is the leading cause of nontraumatic neurological disability in young adults in North America and Europe, affecting more than two million people worldwide (Hauser and Oksenberg, 2006; Noseworthy, 1999; Noseworthy et al., 2000; Trapp and Nave, 2008; Weinshenker, 1998) . Although descriptions of putative MS date back as early as the middle ages, the first pathological report was published by Jean-Martin Charcot, Professor of Neurology at the University of Paris, in 1868 in the Leçons du mardi (Charcot, 1868). He documented characteristic 'plaques' thereby coining the definition of 'la sclerose en plaques' upon examination of a young woman's brain. His diagnostic criteria based on nystagmus, intention tremor and scanning speech are still helpful in recognizing the disease. Although considerable scientific progress has been obtained through over a century of subsequent research, the underlying cause of MS is still unknown.
Pathologically, the diagnosis of MS is confirmed by the presence of multifocal inflammatory demyelinated plaques distributed over time and space within the CNS. Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system. Due to its high prevalence, MS is the leading cause of non-traumatic neurological disability in young adults in the United States and Europe. The clinical disease course is variable and starts with reversible episodes of neurological disability in the third or fourth decade of life. This transforms into a disease of continuous and irreversible neurological decline by the sixth or seventh decade. Available therapies for MS patients have little benefit for patients who enter this irreversible phase of the disease. It is well established that irreversible loss of axons and neurons are the major cause of the irreversible and progressive neurological decline that most MS patients endure. This review discusses the etiology, mechanisms and progress made in determining the cause of axonal and neuronal loss in MS.
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